The description and analysis of inborn errors of human NF-κB--mediated immunity began in 2001 with the discovery of X-linked recessive anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) caused by hypomorphic mutations in *NEMO* (encoding NF-κB essential modulator; [@bib18]), followed by the description of autosomal dominant EDA-ID caused by hypermorphic mutations of the *NFKBIA* gene (encoding IκBα) in 2003 ([@bib16]). These defects lead to a broad range of infections, caused by impaired signaling by various membrane receptors involved in innate and adaptive immunity, including TLR/IL1R and TNFRs ([@bib54]; [@bib13]; [@bib52]; [@bib10]). Gain-of-function mutations of IκBα are also associated with a profound T cell deficiency ([@bib16]). Other global defects of NF-κB activation were later discovered, including autosomal recessive IKKβ deficiency ([@bib48]; [@bib45]; [@bib46]) in the canonical pathway and autosomal-dominant NFKB2 deficiency ([@bib37]; [@bib41]) and autosomal recessive NIK deficiency ([@bib68]) in the alternative pathway.

There are many more inborn errors of specific pathways involving NF-κB caused by mutations in receptors or their ligands, such as CD40 ([@bib21]) and CD40L ([@bib5]; [@bib17]) deficiency. Mutations may also affect cytosolic components, as illustrated by defects of TLR/IL-1-dependent NF-κB--mediated immunity in patients with autosomal recessive IRAK-4 and MyD88 deficiencies ([@bib50]; [@bib66]; [@bib51]; [@bib13]; [@bib6]). Patients with these two deficiencies are prone to life-threatening pyogenic bacterial diseases ([@bib51]). In these inborn errors of immunity, signs of inflammation during infection are either absent or delayed ([@bib52]). Collectively, these experiments of nature highlight the diversity of cells and receptors that engage NF-κB activation. They provide some explanation for some of the clinical phenotypes seen in patients with inborn errors of core NF-κB components. However, most of these receptors can normally also engage other signaling pathways, somewhat blurring some of the latter clinical phenotypes.

Surprisingly, bi-allelic mutations of *HOIL1*, encoding one of the three proteins of the linear ubiquitination chain assembly complex (LUBAC), a component of the NF-κB cascade involved in IKK complex activation ([@bib33]; [@bib64]; [@bib22]; [@bib53]), were recently shown to underlie autoinflammation, immunodeficiency, and amylopectinosis ([@bib9]). The assembly of LUBAC was impaired but its function was not tested. The fibroblasts of HOIL-1--deficient patients display impaired responses to TLR agonists, IL-1β, and TNF, and their B cells display an impaired response to CD40L. In contrast, monocytes from these patients respond more strongly than control monocytes to IL-1β ([@bib9]). Similar findings were recently documented in a mouse model ([@bib42]). We report here a patient with diffuse autoinflammation, combined immunodeficiency, infections, subclinical amylopectinosis, and systemic lymphangiectasia due to a homozygous missense mutation of *HOIP* (*RNF31*), encoding the catalytic component of LUBAC.

RESULTS
=======

Identification of a homozygous *HOIP* missense mutation
-------------------------------------------------------

We investigated a patient born to consanguineous parents of Kuwaiti descent, who presented with multiorgan autoinflammation, systemic lymphangiectasia, weakness at lower extremities, subclinical amylopectinosis, and a combined immunodeficiency manifesting as chronic diarrhea and recurrent viral and bacterial infections, associated with lymphopenia, antibody deficiency and an impaired distribution and function of T lymphocytes (see case report and [Table S1](http://www.jem.org/cgi/content/full/jem.20141130/DC1){#supp1}). Periodic Acid-Schiff staining of sternocleidomastoid muscular biopsy showed patches of granular or subsarcolemmal PAS-positive material that was resistant to treatment with diastase, consistent with amylopectinosis, but there were no clinical, electrographic, or echographic signs of skeletal myopathy or cardiomyopathy ([Fig. 1 A](#fig1){ref-type="fig"}). We set out to decipher the underlying genetic defect by genome-wide linkage (GWL) and whole-exome sequencing (WES; [@bib11]; [@bib12]; [@bib32]; [@bib14]; [@bib15]). We did not find rare variants in known autoinflammation and immunodeficiency genes ([@bib3]; [@bib15]) and in known lymphangiectasia-causing genes (*CCBE1*, *FOXC2*, *VEGFR3*, *SOX18,* and *GJC2*; [@bib4]). We hypothesized that this novel, rare condition would follow an autosomal recessive inheritance. We therefore filtered out all heterozygous and common variant. We found 38 homozygous rare variants in as many genes (minor allele frequency ≤1%; [Table S2](http://www.jem.org/cgi/content/full/jem.20141130/DC1){#supp2}). GWL by homozygosity mapping with a model of complete penetrance further reduced the list of variations to 15 candidate genes (Table S2). These variants included a homozygous T-to-C substitution at position 215 (c.215T\>C) in exon 2 of *HOIP* (also known as *RNF31*), which was identified in the patient and confirmed by Sanger sequencing ([Fig. 1, B and C](#fig1){ref-type="fig"}). This missense substitution results in the replacement of a leucine residue by a proline residue at the start of the PUB (PNGase \[peptide N-glycosidase\]/ubiquitin-associated) domain of HOIP ([Fig. 1 D](#fig1){ref-type="fig"}). Both parents and the healthy sibling of the patient were heterozygous for the mutation ([Fig. 1, B and C](#fig1){ref-type="fig"}). The HOIP L72P variant was not found in public databases (NCBI, UCSC, 1000 genomes, or ExAC, reaching a total of up to 60,706 individuals) or in our own WES database (2,212 individuals). Possibly relevant to the patient's clinical phenotype, *HOIP* encodes HOIL-1--interacting protein, the catalytic components of LUBAC, an E3 ligase complex ([Fig. 1 D](#fig1){ref-type="fig"}) responsible for adding head-to-tail linear polyubiquitin chains to substrate proteins, including NEMO ([@bib36]; [@bib33]; [@bib64]; [@bib61]; [@bib57]), RIP1 ([@bib24]), and ASC ([@bib8]; [@bib56]). No rare mutations were found in HOIL-1 and SHARPIN. The HOIP missense mutation affects the conserved PUB domain of HOIP ([Fig. 1 E](#fig1){ref-type="fig"}), which has recently been shown to be important for the interaction of HOIP with OTULIN and CYLD, two deubiquitinases ([@bib20]; [@bib22]; [@bib58]). SIFT and Polyphen algorithms predicted a deleterious impact of this mutation on the function of the N-terminal domain (Table S2). Finally, the combined annotation dependent depletion score, a method for integrating many diverse annotations into a single measure ([@bib35]), predicted a deleterious impact of the L72P missense mutation (score of 22.2). Moreover, the *HOIP* gene does not harbor overtly deleterious mutations (nonsense, indels, essential splice mutations) at MAF higher than 1/100,000 in public and in-house databases, further suggesting that homozygosity for the L72P HOIP mutation could be disease-causing in the patient.

![**A patient with a homozygous germline *HOIP* mutation.** (A) Amylopectin accumulation in bowel tissue from HOIP-deficient patient. Patient sternocleidomastoid muscular biopsy was stained with hematoxylin and eosin (H&E), or with periodic acid-Schiff stain (PAS) after diastase pretreatment (PASD). A patchy accumulation of PAS+diastase-resistant material in a scattered muscle fibers is shown in patient' biopsy. Bar, 50 µm. (B) Pedigree of the kindred, showing segregation of the L72P missense mutation. (C) *HOIP* DNA sequence electropherograms, for controls, the patient and her family. (D) Schematic diagram of the LUBAC complex. The domains identified are depicted as boxes: PNGase/UBA or UBX (PUB), ubiquitin-like (UBL), novel zinc-finger (NZF), really interesting new gene (RING) domain, in-between RING (IBR) domain, zinc finger (ZF). The red star indicates the position of the L72P mutation. Double arrows indicate the domain involved in the interaction between subunits. (E) Amino acid sequences alignment of the PUB domain of HOIP orthologues. The L72 residue is highlighted in red. The hashtags indicate the amino acids conserved in all proteins containing a PUB domain.](JEM_20141130R_Fig1){#fig1}

Impaired HOIP and LUBAC expression
----------------------------------

We first assessed the impact of the mutation by analyzing *HOIP* mRNA levels by reverse transcription-quantitative PCR in SV40-transformed fibroblasts from patients and controls. The patient's cells contained ∼50% less *HOIP* mRNA than control cells ([Fig. 2 A](#fig2){ref-type="fig"}). This mutation is located close to the acceptor splicing site of exon 2 (+6). We therefore also amplified and sequenced the full-length cDNA, but no splicing defect was detected (unpublished data). Examination of HOIP protein levels by immunoblotting revealed that no mutant protein was detected ([Fig. 2 B](#fig2){ref-type="fig"}) in patient's fibroblasts and EBV-B--transformed cells. We failed to restore the expression of the HOIP L72P protein in the patient's fibroblasts by inhibiting proteasome-, lysosome-, or autophagy-mediated protein clearance with MG-132, leupeptin, or 3-Methyladenine, respectively (unpublished data). This suggests that translation of HOIP L72P mRNAs, or stability of nascent L72P proteins, or both, is impaired. LUBAC contains three subunits: HOIP, HOIL-1, and the SHANK-associated RH domain-interacting protein (SHARPIN; [@bib36]; [@bib33]; [@bib24]; [@bib31]; [@bib65]; [@bib62]). We assessed the abundance of the other two components of LUBAC in control and patient's fibroblasts and EBV-B cells. SHARPIN and HOIL-1 protein levels were lower in the cells from the patient than in control cells ([Fig. 2 B](#fig2){ref-type="fig"}). We investigated the composition of LUBAC in the patient's cells further by performing immunoprecipitation experiments with antibodies against HOIP and SHARPIN, and monitoring the levels of the other two components of the complex. Only trace amounts of HOIP were detected in the patient's fibroblasts and EBV-B cells ([Fig. 2 C](#fig2){ref-type="fig"}). However, HOIL-1 and SHARPIN were still found to be associated as previously shown ([@bib31]). Interestingly, although HOIL-1 was detected as a doublet in SDS-PAGE gels for control cells, only the lower MW product was associated with SHARPIN in the patient's cells ([Fig. 2 B](#fig2){ref-type="fig"}). Thus, the L72P mutation destabilizes the HOIP protein and, consequently, the overall LUBAC complex. These findings suggest that the L72P allele of HOIP is almost loss-of-expression.

![**HOIP deficiency**. (A) Relative HOIP mRNA levels in SV40-immortalized fibroblasts from controls, the HOIP-deficient patient (Patient), and HOIL-1--deficient patients (two independent experiments). (B) Expression of LUBAC subunits in control, HOIP-, and HOIL-1--deficient fibroblasts (left) and control and HOIP-deficient EBV-B cells (right) by immunoblotting total cell extracts with the indicated antibodies (two independent experiments). (C) Immunoblot of immunoprecipitated extracts from control, HOIP-, and HOIL-1--deficient fibroblasts (left) and control and HOIP-deficient EBV-B cells (right) with antibodies directed against HOIP (IP-HOIP) or SHARPIN (IP-SHARPIN) and detected with HOIL-1, HOIP, or SHARPIN antibodies (two independent experiments).](JEM_20141130_Fig2){#fig2}

Impaired NF-κB activation in the patient's fibroblasts
------------------------------------------------------

LUBAC regulates activation of the canonical NF-κB pathway, which plays a key role in inflammatory and immune responses ([@bib64]; [@bib24]). We therefore assessed the functionality of the canonical NF-κB pathway in patient-derived SV40-transformed fibroblasts. Cells from a HOIL-1--deficient patient were also included in this study ([@bib9]). The HOIP-mutated patient's fibroblasts displayed impaired IKK phosphorylation and delayed IκBα degradation in response to TNF or IL-1β, as observed for HOIL-1--deficient fibroblasts ([Fig. 3 A](#fig3){ref-type="fig"}). These cells also displayed a marked impairment of IL-6 production after stimulation with TNF and IL-1β, as shown by ELISA ([Fig. 3 B](#fig3){ref-type="fig"}). Again, these findings were similar to those for HOIL-1--deficient cells. Using confocal microscopy, we recently showed that, in response to cytokine stimulation, the IKK complex is rapidly and transiently relocalized and activated into supramolecular complexes ([@bib63]), which act as a marker of the early steps of NF-κB activation. As already reported for HOIL-1--deficient fibroblasts ([@bib63]), we found that the IL-1 β--induced formation of NEMO-containing structures was almost entirely abolished in HOIP L72P-expressing fibroblasts ([Fig. 3 C](#fig3){ref-type="fig"}), whereas NEMO-containing complexes formed normally in the same cells treated with TNF. Finally, we examined the formation of linear polyubiquitin chains in control and HOIP-deficient fibroblasts treated with cytokines. Using an antibody that specifically recognizes linear polyubiquitin linkages ([@bib43]), we detected linear polyubiquitin aggregates in TNF- and IL-1β--treated control cells, but almost none in the patient's cells ([Fig. 3 D](#fig3){ref-type="fig"}). Overall, these data indicate that linear ubiquitination and NF-κB activation by IL-1β and TNF is impaired in fibroblasts from the patient with the *HOIP* mutation. Moreover, the IL-1β response is more severely affected than the TNF response, as previously shown for HOIL-1 deficiency ([@bib9]). Overall, these findings show that the fibroblastic phenotype of HOIP-mutated patients is as severe as that of HOIL-1--deficient patients, suggesting that the HOIP allele is at least strongly hypomorphic and perhaps completely loss-of-function.

![**Impaired TNF- and IL-1β-induced NF-κB activation in the HOIP-deficient patient.** (A) Time-course of IL-1β--stimulated (left) or TNF-stimulated (right) SV40-immortalized fibroblasts from control, HOIP-, and HOIL-1--deficient patients, with immunoblotting for phospho-IKK (p-IKK), IKKβ, IκBα, NEMO, and β-tubulin. (B) IL-6 production upon stimulation with TNF and IL-1β in SV-40 fibroblasts from two controls, HOIP- (Patient), HOIL-1--, and NEMO-deficient patients (errors bars indicate the SEM; 3 independent experiments). Unpaired Student's *t* tests were performed for the statistical analysis (\*\*, P \< 0.01; \*\*\*, P \< 0.001). (C) Impaired recruitment of NEMO to punctate structures in the patient's fibroblasts. TNF- or IL-1β--stimulated cells were permeabilized with saponin before fixation, and immunolocalization with anti-NEMO antibody (white) was performed. Nuclei were stained with DAPI. Bar, 10 µm. (D) Absence of linear polyubiquitination in the patients' fibroblasts upon TNF or IL-1β stimulation. Immunolocalization with anti-linear ubiquitin chains antibody (red) was performed as in C. Nuclei were stained with DAPI. Bars, 10 µm.](JEM_20141130_Fig3){#fig3}

Restoration of LUBAC stability and NF-κB activation by the wild-type *HOIP* allele
----------------------------------------------------------------------------------

The L72P missense mutation is responsible for the destabilization of HOIP and, consequently, of the other two LUBAC subunits and the whole LUBAC complex, impairing NF-κB responses. In an attempt to rescue the biochemical and cellular phenotype, we reintroduced WT HOIP (N-terminally tagged), by retroviral transduction, into control, HOIP-, and HOIL-1--deficient fibroblasts. This genetic complementation led to the reappearance of the higher molecular weight HOIL-1 protein species on immunoblots ([Fig. 4 A](#fig4){ref-type="fig"}). It also led to the stabilization of SHARPIN not only in patient cells, but also in HOIL-1^−/−^ cells. Moreover, it led to an increase in the phosphorylation of IKK kinases and faster IκBα degradation, similar to that reported for control cells stimulated with TNF or IL-1β ([Fig. 4 B](#fig4){ref-type="fig"}). Finally, cells from the patient complemented with the WT *HOIP* allele produced similar amounts of IL-6 to control cells in response to stimulation with TNF or IL-1β ([Fig. 4 C](#fig4){ref-type="fig"}). In contrast, the introduction of WT *HOIP* into HOIL-1--deficient cells did not restore the production of IL-6 in response to stimulation with TNF or IL-1β, highlighting the nonredundant role of HOIL-1 and HOIP in NF-κB activation ([Fig. 4 C](#fig4){ref-type="fig"}). Overall, these data confirm that the missense L72P mutation of *HOIP* is responsible for both the destabilization of LUBAC and the impairment of NF-κB activation in fibroblasts.

![**Complementation of impaired NF-κB activation by reintroduction of the WT *HOIP* allele.** (A) Immunoblot of the three LUBAC subunits in SV-40--immortalized fibroblasts from control, HOIP-deficient (Patient), and HOIL-1--deficient cells expressing empty vector (-) or WT-V5 HOIP constructs (+). (B) Time course of IL-1β−stimulated (top) or TNF-stimulated (bottom) SV-40--immortalized fibroblasts from control, HOIP-deficient (Patient-empty), and HOIP-deficient cells complemented with WT HOIP (Patient-HOIP), with immunoblotting for p-IKK, IKKβ, IκBα, and GAPDH. (C) IL-6 production in SV-40 fibroblasts from control, HOIP- (Patient), or HOIL-1--deficient patients without (-) and with (+) WT HOIP complementation, after stimulation with TNF or IL-1β. Errors bars represent the SEM (five independent experiments). Unpaired Student's *t t*ests were used for the statistical analysis (\*\*, P \< 0.01; \*\*\*, P \< 0.001; ns, not significant).](JEM_20141130R_Fig4){#fig4}

HOIP-deficient B cells do not respond to CD40L stimulation
----------------------------------------------------------

The HOIP-deficient patient has hypogammaglobulinemia and nonprotective antibody responses to *Streptococcus pneumoniae* and *Haemophilus influenzae*. LUBAC has been shown to be important for the activation of B cells via the CD40 pathway in mice ([@bib29], [@bib30]; [@bib57]) and in humans ([@bib9]). We therefore investigated the possible impairment of CD40 signaling in primary B cells from the HOIP-deficient patient. The stimulation of control B cells with CD40L plus IL-21 or CD40L plus IL-4 led to an increase in CD80 expression, as previously reported ([@bib34]). In contrast, a marked impairment of CD80 up-regulation was observed with B cells from the patient ([Fig. 5 A](#fig5){ref-type="fig"}). Nevertheless, they were able to respond to BCR stimulation (anti-IgM plus CpG ± BAFF), suggesting that BCR activation is only partially dependent on LUBAC ([Fig. 5 A](#fig5){ref-type="fig"}). Stimulation of PBMCs with CD40L plus IL-21 is also known to induce differentiation of primary naive B cells to plasmablasts ([@bib55]). We therefore explored plasmablast generation after stimulation of control and patient PBMCs with CD40L plus IL-21. After 7 d, the proportion of CD19^+^ B cells that were also CD27^hi^ CD38^hi^ (identifying plasmablasts) was markedly lower for the patient than for the control ([Fig. 5 B](#fig5){ref-type="fig"}). We further tested the activation of the canonical NF-κB pathway upon stimulation by CD40L in EBV-B cells from the patient. We found reduced IκBα degradation and impaired phosphorylation of IKKs in HOIP-mutated cells, when compared with abolished signalization in CD40-deficient cells and normal signalization in control cells ([Fig. 5 C](#fig5){ref-type="fig"}). HOIP is thus essential for CD40 activation in human B cells, perhaps accounting at least in part for the patient's hypogammaglobulinemia and nonprotective antibody responses to *S. pneumoniae* and *H. influenzae*.

![**Impaired B cell activation in the HOIP-deficient patient.** (A) Flow cytometry analysis of CD80 expression from stimulated PBMCs. PBMCs left unstimulated or stimulated for 3 d as indicated were stained for CD19 and with either an isotype control (red histograms) or an antibody directed against CD80 (blue histograms). CD80 expression values (CD80 median, isotype median) are indicated under the histograms (one experiment). (B) Flow cytometry analysis of CD27/CD38 expression on gated CD19^+^ cells, upon stimulation of PBMCs for 7 d with CD40L+IL-21 or with medium alone. The gated populations in the figure correspond to CD38^hi^ and CD27^hi^ plasmablasts (one experiment). (C) Time course of CD40L-stimulated EBV-immortalized B cells from control, HOIP- (patient), and CD40-deficient (CD40^−/−^) patients, followed by immunoblotting for p-IKK, IKKβ, IκBα, and GAPDH (two independent experiments).](JEM_20141130_Fig5){#fig5}

Enhanced response to IL-1β in HOIP-deficient monocytes
------------------------------------------------------

We then investigated the cellular basis for the inflammatory phenotype observed in the HOIP-deficient patient (see case report in Discussion). Upon stimulation in vitro with IL-1β for 48 h, the patient's PBMCs produced similar amounts of IL-6 and IL-10 than controls ([Fig. 6 A](#fig6){ref-type="fig"}). In contrast, the patient's cells failed to produce IL-10 in response to TNF ([Fig. 6 A](#fig6){ref-type="fig"}). Monocytes from HOIL-1--deficient patients have been reported to be hyperresponsive to IL-1β, probably accounting for the clinical autoinflammation observed in these patients ([@bib9]). We thus investigated the response of various leukocyte subsets from the HOIP-deficient patient, healthy controls, and IRAK4-deficient patients to in vitro stimulation with TNF, IL-1β, LPS, or a combination of PMA, ionomycin, and CpG-B. The various PBMC subsets were identified on the basis of cell surface expression of the following markers: CD3 (T cells), CD19 (B cells), CD56 (NK cells), and CD14 (monocytes). The production of IL-6, IL-8, MIP-1α, MIP-1β, IL-1β, and IFN-γ was assessed by intracellular staining and flow cytometry. Upon IL-1β stimulation, the proportion of monocytes producing IL-6 and IL-1β was higher in the patient than in healthy controls (13.1 ± 4% vs. 4.4 ± 1.0%, and 29.7 ± 8% vs. 13.8 ± 1.8%, respectively), whereas IRAK-4--deficient monocytes were unresponsive ([Fig. 6 B](#fig6){ref-type="fig"}). Moreover, the patient's monocytes produced IL-8 and MIP-1β in amounts similar to those for the control ([Fig. 6 B](#fig6){ref-type="fig"}). In conclusion, whole blood and PBMCs from the HOIP-deficient patient appear to respond strongly to IL-1β, like HOIL-1--deficient cells, potentially accounting for the clinical autoinflammation observed in this patient.

![**Hyperproduction of IL-6 upon IL-1β stimulation in HOIP-deficient monocytes.** (A) Production of IL-6 and IL-10 by whole blood cells after 48 h of stimulation with TNF, IL-1β, LPS, and PMA/ionomycin in 32 controls (left), 2 travel controls (middle), and the HOIP-deficient patient (right, in red, 1 experiment). (B) Cytokine production in CD14^+^ cell subsets, as determined by intracellular FACS staining of stimulated PBMCs. PBMCs from 12 healthy controls (black), the HOIP-deficient patient (red), an HOIL-1--deficient patient (blue), and an IRAK-4--deficient patient (gray) were stimulated with TNF, IL-1β, or LPS. The secretory pathways were concomitantly blocked with monensin and Brefeldin A. 12 h after stimulation, the cells were immunolabeled with antibodies against CD14 and then permeabilized to assess the production of IL-6, IL-1β, IL-8, and MIP-1β by intracellular immunostaining. Labeled cells were analyzed by flow cytometry (3 independent experiments; \*\*, P \< 0.01).](JEM_20141130_Fig6){#fig6}

DISCUSSION
==========

We have identified the first case of autosomal recessive HOIP deficiency in a patient with systemic autoinflammation, combined immunodeficiency, systemic lymphangiectasia, and mild amylopectinosis. Our study fulfills the criteria for genetic studies in single patients ([@bib14]). HOIP, HOIL-1, and SHARPIN are the three components of LUBAC, the E3-ligase complex responsible for linear ubiquitination ([@bib33]; [@bib24]; [@bib31]; [@bib65]). We found that L72P mutation destabilized HOIP and, consequently, SHARPIN and HOIL-1. This situation is reminiscent of humans with inherited HOIL-1 deficiency ([@bib9]). In *Hoil1* ([@bib64]), *Sharpin* ([@bib24]), and *Hoip* ([@bib49]) knockout mice, and in B cell-specific conditional *Hoip* knockout mice ([@bib57]), the absence of one subunit of LUBAC impairs the expression of the other two subunits, suggesting that LUBAC is a ternary complex in both mice and humans. LUBAC is involved in the NF-κB pathway, in which it conjugates linear polyubiquitin chains to specific Lys residues of NEMO ([@bib64]) and RIP1 ([@bib24]). This activity is essential for full NF-κB activation in mice ([@bib64]; [@bib31]; [@bib69]). We showed in human HOIP-deficient fibroblasts that LUBAC expression and TNF- and IL-1β-driven NF-κB activation are impaired, as in HOIL-1--deficient patients. We also showed that linear ubiquitination is actually abolished in HOIP-deficient fibroblasts, which we had shown only recently for HOIL-1 deficiency ([@bib9]; [@bib63]), connecting this biological activity with NF-κB activation in humans. Overall, our results demonstrate that human HOIP and HOIL-1 are both essential for LUBAC activity and for TNF-, IL-1β--, and CD40L-induced NF-κB responses, at least in fibroblasts and B cells.

This HOIP-deficient patient displayed autoinflammation, like three patients with HOIL-1 deficiency ([@bib9]). The apparent lack of autoinflammation (and immunodeficiency) in most of the other patients carrying bi-allelic mutations in HOIL-1 ([@bib47]; [@bib67]) may result from insufficient clinical characterization from at least one mutant allele being hypomorphic, from the impact of genetic modifiers, or from differences in the exposure to microbial infections ([@bib42]). At any rate, the unusual association of IL-1β hyporesponsiveness in fibroblasts and hyperresponsiveness in monocytes from HOIP- or HOIL-1--deficient patients may be responsible for autoinflammation. In particular, we confirmed that the absence of LUBAC (or its presence in only very small amounts) leads to the overexpression of inflammatory genes and IL-1β hyperresponsiveness in mononuclear leukocytes, including monocytes in particular. *Hoip*^−/−^ mice die during embryonic development ([@bib57]; [@bib49]), unlike *Hoil1*^−/−^ and *Sharpin*^−/−^ mice ([@bib26]; [@bib64]). The HOIP-deficient patient has several features in common with *Hoil1^−/−^* ([@bib42]) and *Sharpin^−/−^* mice ([@bib27], [@bib28]; [@bib59]; [@bib24]; [@bib31]; [@bib40]; [@bib65]), which display chronic severe eosinophilic inflammation. The production of proinflammatory cytokines upon IL-1β stimulation was not investigated in monocytes from *Sharpin* knockout mice, but the inflammatory phenotype of these mice was partially rescued by *Il1rap* ([@bib40]) or *Tnf* ([@bib24]) inactivation, or treatment with the proteasome inhibitor bortezomib, which inhibits NF-κB activation ([@bib40]). The autoinflammation associated with LUBAC deficiency may be caused by NF-κB over-activation in response to certain stimuli in some cell types. These data provide interesting possibilities for therapeutic intervention.

Both HOIL-1-- and HOIP-deficient patients had neonatal bacterial infections and impaired antibody response to *S. pneumoniae* and *H. influenzae* ([@bib9]). The HOIP-deficient patient also presented a broad impairment of antibody production not seen in HOIL-1--deficient patients, a slight excess of naive and transitional B cells and distinctive defects of CD40-dependent B cell activation and plasmablast differentiation. Interestingly, B cell-specific *Hoip* knockout mice have low levels of peritoneal B1 cells and markedly decreased serum levels of all immunoglobulin isotypes, probably due to a defect of the CD40 pathway ([@bib57]). Moreover, the HOIP-deficient patient had severe T cell lymphopenia, affecting the naive compartment in particular, accompanied by an increase in the proportions of effector memory CD4^+^ and T~EMRA~ CD8^+^ cells. These abnormalities have not been observed in patients with HOIL-1 deficiency. However, in the Jurkat T cell line, HOIP knockdown impairs NF-κB activation upon TCR activation ([@bib19]). Moreover, human inborn defects of NF-κB signaling can lead to T cell defects, as seen with IκBα gain-of-function ([@bib16]) or IKKβ loss-of-function mutations ([@bib48]; [@bib45]; [@bib46]). Overt T cell deficiency is more rarely seen in patients with hypomorphic mutations in NEMO ([@bib18]; [@bib13]). Overall, inborn errors of LUBAC, like inborn errors of NF-κB, may underlie T cell deficiencies, a feature that apparently depends on the nature of the disease-causing gene.

Systemic lymphangiectasia may have also contributed to T cell lymphopenia in this patient, by lymphatic leak ([@bib23]). Lymphangiectasia has not been observed in HOIL-1--deficient patients ([@bib9]; [@bib47]; [@bib67]) and in *Hoil*^−/−^ mice ([@bib64]). Although lymphangiectasia has not been reported in *Sharpin*^−/−^ mice, they display dilation of the dermal, mouth, esophagus, and stomach capillaries ([@bib26]), similar to this patient's intestinal capillaries (see Case report). Moreover, *Hoip*^−/−^ mice die in utero due to disrupted vasculature caused by TNFR1-mediated endothelial cell death ([@bib49]). Conditional endothelial cell IKKβ KO mice also exhibit increased vasculature permeability ([@bib7]). Improper TNFR1 signaling seems to activate aberrant responses, in particular the formation of cytoplasmic complex II, triggering cell death. Overall, the circulatory and lymph vessel phenotypes of *Hoip*-deficient mice and HOIP-deficient patients suggest that HOIP, alone or less likely as a subunit of LUBAC, may regulate these systems. Finally, the HOIP-deficient patient displayed patches of cellular amylopectinosis, with muscular weakness at the lower extremities, but normal electromyography, and without clinical or echographic signs of cardiomyopathy. This contrasts with HOIL-1--deficient patients, whose amylopectinosis was an early onset, severe, and consistent manifestation, even in patients whose mutations were not proven to be loss-of-function ([@bib9]; [@bib47]; [@bib67]). The milder amylopectinosis in the HOIP-deficient patient suggests that amylopectinosis may be more dependent on HOIL-1 than HOIP, LUBAC, and NF-κB. Alternatively, the HOIP L72P mutation may not be completely loss-of-function.

Case report
-----------

The patient, a 19-yr-old woman of Kuwaiti origin, was born at term, after a twin pregnancy. Her parents are first cousins and her twin brother is healthy. During the neonatal period, she presented omphalitis, requiring antibiotic treatment, and splenomegaly. After discharge, she had recurrent episodes of fever and persistent splenomegaly, associated with mild liver enlargement. At the age of 2 yr, familial Mediterranean fever was suspected, leading to the treatment of the patient for 3 yr with colchicine, with no clinical benefit. From early childhood, the growth of the patient was stunted. At the age of 4 yr, she developed generalized lymphadenopathy after immunization with BCG. 1 yr later, she presented severe respiratory distress, requiring mechanical ventilation. Treatment with rifampicin was initiated for possible mycobacterial disease. At the age of 7 yr, the patient began to suffer from recurrent episodes of fatty diarrhea, associated with fever and oral ulcers. Immunological investigations were performed for the first time at the age of 9 yr and showed T cell lymphopenia (CD3^+^: 776 cells/µl), an impaired proliferative response to anti-CD3 (cpm: 1,106 vs. 35,216 in a normal control), and hypogammaglobulinemia (IgG: 315 mg/dl), associated with nonprotective antibody responses to *S. pneumoniae* and *H. influenzae*, but with a good antibody response to tetanus toxoid. Prophylaxis with cotrimoxazole was initiated. Additional abnormalities identified in laboratory tests included hypoalbuminemia (2.6 g/dl), hypocalcemia (8.2 mg/dl), anemia (Hb, 8.1 g/dl), iron deficiency (3.7 µmol/l), vitamin 25-OH D3 deficiency (7 nmol/l; n.v., 75--125 nmol/l), and an elevated ESR (97 mm/h) and high C-reactive protein (CRP) serum level (8.06 mg/dl). Endoscopies of the upper and lower gastrointestinal tract were unremarkable. The poor growth of the patient led to treatment with human recombinant growth hormone (hrGR). However, this treatment was complicated by femur fractures, leading to its cessation. At 15 yr of age, the patient complained of severe pain in the hips, knees, and ankles. Treatment with a nonsteroidal antiinflammatory drug (naproxen) led to clinical improvement, but was complicated by gastrointestinal bleeding. Recurrent episodes of diarrhea and edema, requiring frequent infusions of albumin and furosemide, led to additional investigations. Negative results were repeatedly obtained for endoscopy, but videocapsule endoscopy, at the age of 16 yr, showed patchy areas of white-tipped thickened villi throughout most of the small bowel, consistent with intestinal lymphangiectasia. Further evidence of lymph vessel abnormalities was provided by a lymphangiogram (showing abnormal filling of the thoracic duct), high α-1-antitrypsin antibody, and triglyceride concentrations. The patient was placed on a low-fat, high-protein diet, with some improvement, but she continued to suffer from fatty diarrhea, with poor weight gain and impaired linear growth. She also developed persistent warts. A chest CT scan at the age of 17 yr demonstrated mild bronchiectasis in the right middle and lower lobes. Laboratory examinations at 18 yr of age confirmed the T and B cell abnormalities (Table S2), associated with elevated fluctuating but consistently high ESR (between 26 and 119 mm/h), increased CRP concentration (between 1.22 and 12.68 mg/dl; normal values: ≤0.5 mg/dl), and haptoglobin concentration (275 mg/dl; normal range: 33--183 mg/dl). Treatment with intravenous immunoglobulins was initiated, leading to an improvement in IgG trough levels. However, the episodes of systemic edema persisted, although at a lower frequency. The most recent follow-up visit showed a worsening of intestinal lymphangiectasia. An endoscopy with biopsies showed dilated lymphatic space in duodenal, small intestinal, and colonic mucosa. Moreover, the patient was suffering from muscular weakness, especially in the lower extremities. An MRI of the pelvis demonstrated diffuse muscular atrophy, with fatty infiltration of the gluteal musculature and the abductors. However, motor and sensory conduction and needle electromyography were normal, and there was no evidence of cardiomyopathy at heart ultrasound. Creatine phosphokinase (CK) and LDH levels are within the normal limits. Pulmonary function tests have shown reduced forced expiratory volume (78% of predicted), but to a lower extent than has been reported in HOIL-1 deficient patients. The patient is still on antibiotic prophylaxis, a low-fat and high-protein diet, iron and vitamin D supplementation, and immunoglobulin replacement therapy, and has started treatment with octreotide.

MATERIALS AND METHODS
=====================

### Sample collection.

This study was conducted in accordance with the Helsinki Declaration, with informed consent obtained from the patient and her family. The study was approved by the local ethics committee of Necker-Enfants Malades Hospital (Paris, France); Boston Children Hospital (Boston, MA); and The Rockefeller University Hospital (New York, NY).

### Genetic analysis.

For WES massively parallel sequencing, genomic DNA extracted from the patient's peripheral blood cells was sheared with a Covaris S2 Ultrasonicator. An adapter-ligated library was prepared with the Paired-End Sample Prep kit V1 (Illumina). Exome capture was performed with the SureSelect Human All Exon kit (Agilent Technologies). Paired-end sequencing was performed on a HiSeq 2500, generating 100-base reads. For sequence alignment, variant calling and annotation, we used BWA aligner ([@bib38]) to align sequences with the human genome reference sequence (hg19 build). Downstream processing was performed with the Genome analysis toolkit (GATK; [@bib44]), SAMtools ([@bib39]), and Picard Tools. Substitution and indel calls were identified with a GATK Unified Genotyper and a GATK Indel GenotyperV2, respectively. All calls with a read coverage ≤2x and a Phred-scaled SNP quality of ≤20 were filtered out. All the variants were annotated with the GATK Genomic Annotator.

For genotyping and linkage analysis, the patient, her parents, and her unaffected brother were genotyped with the Affymetrix GeneChip Human Mapping 250K array. Genotype calling was achieved with Power Tools (Affymetrix). We discarded monomorphic single-nucleotide polymorphisms (SNPs), SNPs with a call rate \<100%, and SNPs presenting more than one Mendelian inconsistency within the family. SNPs were further filtered based on population-based filters, using HapMap CEU trios. Multipoint linkage analysis, assuming autosomal recessive inheritance with complete penetrance (homozygosity mapping), was performed using Merlin software ([@bib2]) on 84,954 high-quality SNPs. Marker--marker linkage disequilibrium was modeled by creating clusters including SNPs for which pairwise r^2^ was greater than 0.4 and all intervening SNPs ([@bib1]).The HapMap CEU trios were used to estimate pairwise r^2^ and haplotype frequencies of the clusters. We used different genomic database: Exome Aggregation Consortium (ExAC), 1000 Genome Project, and dbSNP all accessed in February 2015. CADD score for variation was calculated using the University of Washington's CADD website.

### Cell lines, immortalization, and complementation.

Control and patient-derived fibroblasts were immortalized by transfection with a plasmid encoding the SV40 large-T antigen. Transformed cell lines were grown in DMEM (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen). The human NEMO^−/−^ fibroblasts were provided by A. Smahi (Imagine Institute, Paris, France; [@bib60]). The HOIP-V5 open-reading frame was amplified from a plasmid provided by Henning Walczak and inserted into the retroviral vector pMSCV (Life Science). Infectious viral particles were produced by cotransfecting GP2-293 packaging cells with pVSV-G and pMSCV-HOIP or an empty vector (Life Science). Viral particles were collected 48--72 h after transfection and used to infect SV40-transformed fibroblasts. Infected cells were selected with 0.4 µg/ml puromycin (Invitrogen). B lymphocyte cell lines from the patient and a healthy donor have been immortalized with Epstein-Barr virus and grown in RPMI 1640 (Gibco) supplemented with 15% fetal calf serum (Invitrogen).

### Antibodies and reagents.

The antibodies used for detection on immunoblots were anti-HOIL-1 N-ter, provided by H. Walczak (University College London, London, England, UK; [@bib25]), anti-HOIL-1 C-ter provided by K. Iwai (Graduate School of Medicine, Kyoto University, Kyoto, Japan; [@bib36]), anti-HOIP (PAB6229; Abnova), and anti-linear polyubiquitin chains 1F113F5/Y102L provided by Genentech ([@bib43]), anti-NEMO (sc-8330; Santa Cruz Biotechnology, Inc.; \#611306; BD), anti-SHARPIN (14626--1-AP; ProteinTech), anti-IκBα (\#610690; BD), anti-phospho-IKKα-β (ser176/180; 16A6; Cell Signaling Technology), anti-IKKβ (AM8109a, Abgent), anti-β-tubulin (T4026; Sigma-Aldrich), and anti-GAPDH (sc-365062; Santa Cruz Biotechnology, Inc.) antibodies. Species-specific secondary antibodies coupled to horseradish peroxidase were obtained from Vector Laboratories or Amersham-Pharmacia.

### Immunostaining.

Periodic acid-Shift (PAS) staining was done using a standard clinical histopathology laboratory procedure. Sections of frozen tissue or formalin fixed from a sternocleidomastoid muscle biopsy were deparaffinized and rehydrated, then either rinsed in water or incubated with 1% diastase (Sigma-Aldrich) in distilled water for 60 min at 60°C, followed by rinsing in water for 2 min. Slides were then incubated with 0.5% periodic acid (Poly-Scientific R&D) for 5 min, rinsed four times in distilled water, placed in Schiff's solution (Poly-Scientific R&D) for 15 min, rinsed in tap water for 10 min, counterstained with Harris hematoxylin (Poly-Scientific R&D) for 5 min, and rinsed in water again for 5 min. After quick dipping in 0.5% acid alcohol, slides were extensively rinsed in water before dehydration, clearing, and mounting in permanent mounting media. The presence of amylopectinosis was documented by persistence of PAS-positive material in diastase-treated sections. Images have been captured with an BX43 microscope and DP25 digital camera (both from Olympus).

### Cell lysis, immunoprecipitation, and immunoblotting.

Cells were lysed in a buffer containing 30 mM Tris-HCl, pH 7.5, 120 mM NaCl, 2 mM KCl, 1% Triton X-100, and 2 mM EDTA supplemented with protease and phosphatase inhibitors (Complete and PhoStop; Roche). For immunoprecipitation, antibodies (5 µg) were added to 1 mg of total protein extract and incubated overnight at 4°C. Protein A-- or protein G--coupled agarose beads (Sigma-Aldrich) were added to the samples, which were then incubated for 1 h at 4°C. Beads were washed three times in lysis buffer and resuspended in Laemmli buffer.

### Immunofluorescence.

For immunofluorescence, cells cultured on glass coverslips were treated twice with ice-cold saponin extraction buffer (80 mM Pipes, pH 6.8, 1 mM MgCl~2~, 1 mM EGTA, and 0.1% saponin) for 2 min and 4 min on ice as previously described ([@bib63]). Cells were then washed twice with PBS before fixation in 100% methanol. The cells were progressively rehydrated by successive washes with 85, 70, and 50% ethanol in water and two final washes with PBS. After blocking by incubation with 1% BSA in PBS, the slides were incubated with rabbit anti-NEMO antibodies or with human anti-linear polyubiquitin, washed with PBS and incubated either with anti--rabbit Alexa Fluor 488 or anti--human Alexa Fluor 546 secondary antibodies (Life Technologies). The slides were then washed again and incubated with DAPI (Sigma-Aldrich) to stain the nuclei. The coverslips were mounted in Mowiol supplemented with an anti-fading agent (AF100; Biovalley). Specimens were examined with an ApoTome imaging system (Imager Z1; Carl Zeiss) equipped with a 63×/1.4 oil DIC objective (Carl Zeiss).

### Gene expression and qPCR analysis.

RNA was extracted from SV40-transformed fibroblasts with TRIzol (Invitrogen) and reverse-transcribed (2 µg) with the SuperScript III first-strand synthesis kit (Invitrogen). HOIP expression was quantified by RT-qPCR in a *Taq*Man Gene Expression Assay (Hs00215938_m1, Hs01047328_g1; Life Technologies), with normalization against GUS probes.

### Cell stimulation, ELISA, and FACS analysis.

For whole blood activation, fresh blood was first mixed with an equal volume of RPMI-1640 (Invitrogen), left untreated, or treated with agonists for 48 h. Levels of IL-6 and IL-10 secretion were determined with ELISA kits (M9316 and M1910; Sanquin).

For B cell activation, PBMCs were purified by Ficoll gradient centrifugation, and 10^6^ cells were cultured in 24-well plates within 1 ml RPMI medium per well supplemented with 10% FBS and 50 U/ml penicillin (Invitrogen) and 50 µg/ml streptomycin (Invitrogen). The cells were stimulated for 3 d with CD40L+IL-21, CD40L+IL-4, anti-IgM+CpG, or anti-IgM+Cpg+BAFF (5 µg/ml CD40L, 200 ng/ml IL-21-Fc, BAFF, anti-IgM \[1 µg/ml; Southern Biotech\], CpG \[500 nM; Invivogen\], and IL-4 \[1 ng/ml; R&D Systems\]). PBMCs were harvested, blocked by incubation for 10 min in PBS+10% human serum, and stained by incubation for 30 min on ice, for CD19 (BioLegend), an isotype control or CD80 (eBioscience). Flow cytometry analyses were performed on a BD LSRFortessa flow cytometer (BD). Cells were gated on CD19^+^ and CD80 expression was then analyzed with FlowJo software (Tree Star).

For plasmablast assay, PBMCs were cultured in RPMI supplemented with 10% FBS, 0.025% Hepes, 0.01% PenStrep, 0.01% sodium pyruvate, 0.005% NEAA, 0.005% [l]{.smallcaps}-glutamine, and 0.0013% β-mercaptoethanol) alone (unstimulated cells) or with 200 ng/ml IL-21-Fc and 5 µg/ml CD40 ligand for a total of 7 d. Cells were stained with CD19-PECy5 (BioLegend; clone HIB19), CD27-APC (eBioscience; clone O323), or CD38-PECy7 (BioLegend; clone HIT2) antibodies, and analyzed by flow cytometry on an LSR II machine (BD) with FlowJo software (Tree Star).

For leukocyte activation, frozen PBMCs were washed twice with FCS-containing medium and used to seed 48-well plates (10^6^ cells/well). They were cultured for 4--6 h, and then stimulated with TNF (20 ng/ml; R&D Systems) IL-1β (10 ng/ml; R&D Systems), LPS (10 ng/ml; Sigma-Aldrich), or PMA+ionomycin+CpGB (Sigma-Aldrich; 10^−9^ M + 10^−7^ M + 100 µg/ml). During stimulation, protein transport was blocked with GolgiStop and GolgiPlug (BD). Cells were stained with anti-CD3 (BD; \#560366), anti-CD19 (BD; \#340951), anti-CD14 (BD; \#557742), and anti-CD56 (BioLegend; \#318331) antibodies for cellular phenotyping and with Aqua Live/Dead (Invitrogen) to exclude dead cells. After fixation and permeabilization (BD; \#554722), the cells were stained with antibodies against IL-6 (BD; \#561441), MIP-1β (BD; \#554730), MIP-1β (BD; \#560565), IL-1β (BD; \#340515), IL-8 (BD; \#511410), and IFN-γ (BD; \#559326). Stained PBMCs were captured by flow cytometry with a LSRII flow cytometer (BD) and FACSDiva software (BD). The data were analyzed with FlowJo software (Tree Star).

### Statistics.

GraphPad Prism software was used to conduct unpaired, two-tailed Student's *t* tests for sample analysis or one-way ANOVA followed by Tukey's multiple comparison test. Values of P \< 0.05 were considered significant.

### Online supplemental material.

Table S1, available as an Excel file, shows the immunological profile of the patient. Table S2, available as an Excel file, shows whole-exome sequencing data for the patient. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20141130/DC1>.
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